Immunotherapy for endometrial carcinoma based on molecular typing
10.3760/cma.j.cn371439-20220408-00138
- VernacularTitle:基于分子分型的子宫内膜癌免疫治疗
- Author:
Qiuyue XU
1
;
Xianmei MA
;
Qi YUE
Author Information
1. 哈尔滨医科大学附属第四医院妇产科，哈尔滨 150000
- Keywords:
Endometrial neoplasms;
Molecular typing;
Immunotherapy;
Immune checkpoint inhibitors;
Survival rate
- From:
Journal of International Oncology
2022;49(11):700-704
- CountryChina
- Language:Chinese
-
Abstract:
Endometrial cancer has been identified by The Cancer Genome Atlas program with four molecular subtypes by genome sequence analysis. Clinical trials to select suitable immunotherapeutic agents based on the different immune characteristics of each subtype have been conducted in several countries and have made important progress. The main clinical applications of immune checkpoint inhibitors include anti-programmed cell death protein-1/programmed death-ligand 1 antibodies and poly ADP-ribose polymerase inhibitors. Optimizing drug selection and drug combination based on the target characteristics of different immune checkpoint inhibitors may provide new opportunities for immunotherapy of endometrial cancer and bring new light to improve survival rates.
